JP Morgan Chase
OTLK icon

JP Morgan Chase’s Outlook Therapeutics OTLK Stock Holding History

JP Morgan Chase’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3 Hold
15
– – ﹤0.01% 7467
2025
Q4 		$24 Hold
15
– – ﹤0.01% 7296
2025
Q3 		$16 Hold
15
– – ﹤0.01% 7297
2025
Q2 		$24 Sell
15
-8,388
-100% -$13.4K ﹤0.01% 6947
2025
Q1 		$10.3K Buy
8,403
+914
+12% +$1.6K ﹤0.01% 6303
2024
Q4 		$14.2K Buy
7,489
+343
+5% +$1.41K ﹤0.01% 6316
2024
Q3 		$38.2K Buy
7,146
+3,595
+101% +$26.3K ﹤0.01% 6067
2024
Q2 		$26.2K Sell
3,551
-150
-4% -$1.2K ﹤0.01% 6072
2024
Q1 		$44.2K Sell
3,701
-1,338
-27% -$10.8K ﹤0.01% 5994
2023
Q4 		$39.7K Hold
5,039
– – ﹤0.01% 6066
2023
Q3 		$22.3K Sell
5,039
-987
-16% -$21.8K ﹤0.01% 6044
2023
Q2 		$210K Buy
6,026
+90
+2% +$2.45K ﹤0.01% 5045
2023
Q1 		$129K Buy
5,936
+2,571
+76% +$57.5K ﹤0.01% 5314
2022
Q4 		$72K Buy
3,365
+129
+4% +$2.81K ﹤0.01% 5482
2022
Q3 		$79K Buy
3,236
+67
+2% +$1.56K ﹤0.01% 5393
2022
Q2 		$65K Buy
3,169
+496
+19% +$14.3K ﹤0.01% 5577
2022
Q1 		$95K Buy
2,673
+949
+55% +$29.6K ﹤0.01% 5535
2021
Q4 		$47K Sell
1,724
-567
-25% -$20.2K ﹤0.01% 5971
2021
Q3 		$100K Buy
2,291
+610
+36% +$29.4K ﹤0.01% 5568
2021
Q2 		$84K Buy
+1,681
New +$78K ﹤0.01% 5599

Other funds holding OTLK

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $126M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NMC
Nine Masts Capital Central, Hong Kong $693M AUM 31.93% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

JP Morgan Chase's OTLK Position: Q1 2026 in Review

JP Morgan Chase held its Outlook Therapeutics (OTLK) position steady in Q1 2026 at 15 shares worth $3. The position accounts for ﹤0.01% of the portfolio, ranked #7467.

JP Morgan Chase first reported a position in OTLK in Q2 2021 and has held it in 20 quarters since. The position peaked at $210K in Q2 2023. 54 funds tracked by Wall St. Rank hold OTLK as of Q1 2026.

  • JP Morgan Chase held 15 shares of Outlook Therapeutics worth $3 as of Q1 2026.
  • JP Morgan Chase left its Outlook Therapeutics share count unchanged in Q1 2026.
  • Outlook Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7467 holding.
  • JP Morgan Chase first reported a position in Outlook Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • JP Morgan Chase's Outlook Therapeutics position peaked at $210K in Q2 2023.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.